UN
Unichem Laboratories Ltd (UNICHEMLAB)
₹468.95
Mkt cap
₹3,390 Cr
P/E ratio
28.50
P/B
1.19
Div yield
0.00%
ROE
3.17%
ROCE
4.13%
EPS (TTM)
₹16.45
Book value
₹395
52W range
278–687
Sector
Healthcare
Price history
Previous close
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. [1]
NSE UNICHEMLABBSE 506690
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−31.76% from high₹469
₹278+68.57% from low₹687
Current
₹468.95
Prev close
₹479.25
Day
−2.15%
Price performance
1D
−1.96%
1W
−5.79%
1M
−3.67%
3M
−9.04%
6M
+27.97%
1Y
+0.80%
YTD
+6.15%
Financials
Revenue, profit & margin
P/E ratio
28.5×
UNICHEMLAB is 15% below the sector median of 33.4×
UNICHEMLAB28.5×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 416 | 466 | 432 | 483 | 507 | 533 | 587 | 527 | 579 | 521 | 575 | 633 | 640 | |
| YoY Sales growth | +26% | +54% | +7% | +14% | +22% | +14% | +36% | +9% | +14% | -2% | -2% | +20% | +11% | |
| Expenses | 407 | 435 | 406 | 443 | 452 | 448 | 503 | 504 | 513 | 476 | 527 | 563 | 566 | |
| Operating Profit | 9 | 31 | 25 | 40 | 55 | 86 | 84 | 22 | 66 | 45 | 48 | 70 | 74 | |
| OPM % | 2.1% | 7% | 6% | 8% | 11% | 16% | 14% | 4.3% | 11% | 9% | 8% | 11% | 12% | |
| Other Income | 6 | 79 | -119 | 4 | 9 | 14 | 9 | 7 | -37 | 287 | 11 | 16 | -9 | |
| Interest | 7 | 6 | 5 | 4 | 5 | 7 | 5 | 7 | 8 | 7 | 9 | 7 | 8 | |
| Depreciation | 29 | 32 | 27 | 32 | 32 | 31 | 30 | 32 | 31 | 31 | 31 | 30 | 30 | |
| Profit before tax | -22 | 73 | -126 | 8 | 27 | 62 | 58 | -9 | -11 | 293 | 19 | 49 | 27 | |
| Tax % | 12% | -0% | 3% | 74% | 9% | 6% | 8% | 16% | 10% | 10% | 42% | 15% | 19% | |
| Net Profit | -24 | 73 | -129 | 2 | 25 | 58 | 53 | -10 | -12 | 264 | 11 | 41 | 22 | |
| EPS in Rs | -3.48 | 10.40 | -18.37 | 0.29 | 3.50 | 8.22 | 7.52 | -1.49 | -1.69 | 37.54 | 1.55 | 5.89 | 3.16 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202670.22%Promoter
Promoters70.22%
FIIs2.70%1.80
DIIs9.40%1.06
Public17.67%0.74
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,870.00 | 36.46 | 4,48,676 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,150.00 | 86.62 | 2,95,997 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,668.80 | 81.80 | 1,77,586 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,338.00 | 94.28 | 1,26,325 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,204.20 | 26.51 | 1,20,119 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,388.00 | 41.41 | 1,15,936 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,388.00 | 36.11 | 1,12,135 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Unichem Labs. | ₹481.55 | 28.52 | 3,390 | 0.00% | 22 | −7.46% | 640 | +10.58% | 4.13% |
| Median: 160 Co. | ₹445.73 | 33.35 | 2,016 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts11
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Nov - Publication of Financial Results for quarter and half year ended September 30, 2026, in newspapers.Financial Results For Q2FY27 4 NovBoard Meeting Outcome for Results For Q2 FY2027 4 Nov - Board approved Q2/H1 FY27 results; consolidated PAT 22.22 crore, H1 63.69 crore.Board Meeting Intimation for Board Meeting Intimation For Unaudited Financial Results
(Consolidated And Standalone) For The Second Quarter And Six
Months Ended September 30, 2026. 21 Oct - Board meeting on November 4, 2026 to approve Q2 and six-month FY2026 unaudited results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 13 Oct






